Beaconlight Capital LLC Invests $2.88 Million in TransMedics Group, Inc. $TMDX

Beaconlight Capital LLC bought a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 21,524 shares of the company’s stock, valued at approximately $2,884,000. TransMedics Group accounts for about 1.6% of Beaconlight Capital LLC’s portfolio, making the stock its 21st biggest holding. Beaconlight Capital LLC owned 0.06% of TransMedics Group at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Opal Wealth Advisors LLC acquired a new position in shares of TransMedics Group during the second quarter valued at $26,000. Smartleaf Asset Management LLC grew its position in TransMedics Group by 44.3% in the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock valued at $30,000 after buying an additional 135 shares in the last quarter. Quarry LP increased its stake in TransMedics Group by 88.5% during the 1st quarter. Quarry LP now owns 592 shares of the company’s stock valued at $40,000 after buying an additional 278 shares during the period. Sound Income Strategies LLC bought a new stake in shares of TransMedics Group during the 2nd quarter worth about $48,000. Finally, Elevation Point Wealth Partners LLC acquired a new stake in shares of TransMedics Group in the 2nd quarter worth approximately $48,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Trading Down 0.7%

Shares of TMDX opened at $126.79 on Friday. The business’s 50-day moving average price is $126.72 and its 200 day moving average price is $123.13. The company has a current ratio of 7.69, a quick ratio of 7.13 and a debt-to-equity ratio of 1.43. The stock has a market capitalization of $4.33 billion, a P/E ratio of 51.33 and a beta of 2.06. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $156.00.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.37 by $0.29. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The company had revenue of $143.82 million during the quarter, compared to analysts’ expectations of $145.33 million. During the same period last year, the company posted $0.12 earnings per share. The business’s revenue for the quarter was up 32.2% on a year-over-year basis. Analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Needham & Company LLC raised their price objective on shares of TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Jefferies Financial Group began coverage on TransMedics Group in a research report on Monday, October 13th. They set a “buy” rating and a $145.00 price target on the stock. Stifel Nicolaus initiated coverage on TransMedics Group in a report on Thursday, September 4th. They issued a “hold” rating and a $115.00 price objective for the company. Canaccord Genuity Group raised their target price on TransMedics Group from $142.00 to $147.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Finally, Wall Street Zen upgraded shares of TransMedics Group from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Six analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $136.44.

Insider Activity

In other news, insider Anil P. Ranganath sold 3,000 shares of the stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total value of $435,660.00. Following the completion of the sale, the insider owned 13,955 shares in the company, valued at $2,026,545.10. This represents a 17.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director David Weill sold 5,000 shares of the firm’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total value of $693,200.00. Following the completion of the sale, the director directly owned 12,134 shares of the company’s stock, valued at approximately $1,682,257.76. This trade represents a 29.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 13,062 shares of company stock valued at $1,797,634 in the last 90 days. Company insiders own 7.00% of the company’s stock.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.